Cue Biopharma, Inc. (CUE)
Stock Price:
$11.14 USD
-0.96 (-7.93%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
328.59M |
| Revenue (ttm) |
4.01M |
| Net Income (ttm) |
-39.56M |
| Shares Out |
29.50M |
| EPS (ttm) |
-1.56 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 30, 2020 |
| Last Price |
$11.14 |
| Previous Close |
$12.10 |
| Change ($) |
-0.96 |
| Change (%) |
-7.93% |
| Day's Open |
11.88 |
| Day's Range |
10.75 - 12.23 |
| Day's Volume |
399,077 |
| 52-Week Range |
8.25 - 31.69 |
More Stats
| Market Cap |
328.59M |
| Enterprise Value |
249.52M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
29.50M |
| Float |
26.24M |
| EPS (basic) |
-1.53 |
| EPS (diluted) |
-1.56 |
| FCF / Share |
-1.19 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.61M |
| Short Ratio |
10.40 |
| Short % of Float |
9.95% |
| Beta |
1.86 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
81.98 |
| PB Ratio |
4.45 |
| Revenue |
4.01M |
| Operating Income |
-40.05M |
| Net Income |
-39.56M |
| Free Cash Flow |
-33.62M |
| Net Cash |
79.07M |
| Net Cash / Share |
2.68 |
| Gross Margin |
-599.48% |
| Operating Margin |
-999.08% |
| Profit Margin |
-986.90% |
| FCF Margin |
-838.80% |
| ROA |
-34.98% |
| ROE |
-78.78% |
| ROIC |
-182.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (5)
| Buy |
4 |
| Overweight |
1 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$31.00*
(178.28% upside)
Low
30.0
Current: $11.14
High
33.0
Target: 31.00
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | 3.46 | 1.14 | - | - | - |
| Revenue Growth | 202.67% | - | - | - | - |
| Gross Profit | 3.46 | 1.14 | - | - | - |
| Operating Income | -36.77 | -38.70 | -23.23 | -7.66 | -1.93 |
| Net Income | -36.70 | -38.98 | -23.23 | -7.66 | -1.93 |
| Shares Outstanding | 22.04 | 20.13 | 10.73 | 7.43 | 5.66 |
| Earnings Per Share | -1.66 | -1.94 | -2.16 | -1.03 | -0.34 |
| Operating Cash Flow | -30.80 | -26.41 | -12.14 | -5.97 | -1.66 |
| Capital Expenditures | 0.08 | -1.85 | -1.03 | -0.52 | -0.75 |
| Free Cash Flow | -30.72 | -28.27 | -13.17 | -6.48 | -2.41 |
| Cash & Equivalents | 61.98 | 40.28 | 63.58 | 15.09 | 6.55 |
| Total Debt | 5.80 | - | - | - | - |
| Net Cash / Debt | 56.19 | 40.28 | 63.58 | 15.09 | 6.55 |
| Assets | 71.61 | 45.36 | 66.95 | 16.28 | 7.31 |
| Liabilities | 17.02 | 11.39 | 5.35 | 1.10 | 0.38 |
| Book Value | 54.58 | 33.97 | 61.61 | 15.17 | 6.94 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Cue Biopharma, Inc. |
| Country |
United States |
| Employees |
45 |
| CEO |
Daniel R. Passeri |
Stock Information
| Ticker Symbol |
CUE |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CUE |
| IPO Date |
January 2, 2018 |
Description
Cue Biopharma, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic that is in Phase I clinical trials designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, an onco-fetal viral antigen for cancers, including solid tumors and hematologic malignancies; CUE-103, an antigen; CUE-200 framework that includes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for Immuno-selective targeting and alteration of T cells (STAT) in the field of oncology; and Albert Einstein College of Medicine to develop Immuno-STAT biologics for chronic infectious diseases, as well as a strategic research collaboration with Dr. Michael Dustin and Oxford University. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.